We found varying CTC numbers in patients with vulvar cancer after aRT as well as in patients with cervical cancer after aCRT and pCRT and link the presence of post-therapeutic numbers of an identified PD-L1+ CD49f+ CD133+ CTC subpopulation within the therapy-induced systemic milieu with reduced recurrence free survival. This evidence concerns the gene PROM1 and cervical carcinoma.